Medicure Inc (TSXV:MPH,OTC: MCUJF), a Canada-based cardiovascular pharmaceutical company, announced yesterday its financial results for the nine months ended 30 September 2018.
The company reported net revenues from AGGRASTAT for the nine months ended 30 September 2018 at CAD20.3m compared to CAD22.1m in the year-ago period.
The firm posted adjusted EBITDA for the nine months ended 30 September 2018 at CAD2.2m compared to CAD5.2m for the same period in 2017.
The company reported net income for the nine-month period at CAD2.4m or CAD0.15 per share, compared with a net loss of CAD8.0m or CAD0.52 per share for the year ago period.
The company reported cash and cash equivalents for the period at CAD20,227,835, compared with CAD4,778,772 for the year ago period.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva